No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma
Research output: Contribution to journal › Journal article › Research › peer-review
The response to treatment varies among patients with multiple myeloma and markers for prediction of treatment outcome are highly needed. Bioactivation of cyclophosphamide and thalidomide, and biodegradation of bortezomib, is dependent on cytochrome P450 metabolism. We explored the potential influence of different polymorphisms in the CYP enzymes on the outcome of treatment.
| Original language | English |
|---|---|
| Journal | B M C Cancer |
| Volume | 10 |
| Pages (from-to) | 404 |
| Number of pages | 8 |
| ISSN | 1471-2407 |
| DOIs | |
| Publication status | Published - 4 Aug 2010 |
ID: 34070691